USTR Special 301 Report 2026 — India Retained on Priority Watch List

Why in News

The Office of the United States Trade Representative (USTR) released the 38th annual Special 301 Report — placing India on the Priority Watch List for the 34th consecutive year. In the 2026 report, Vietnam was elevated to Priority Foreign Country (PFC) status — the most serious designation — for the first time since 2013, opening the door to a formal Section 301 investigation. The European Union was added to the Watch List (not Priority Watch List) for the first time, over concerns about Geographical Indications (GI) and pharmaceutical patent linkage.

What is the Special 301 Report?

The Special 301 Report is published annually by the USTR under Section 182 of the Trade Act of 1974 (as amended by the Omnibus Trade and Competitiveness Act of 1988). It identifies countries whose intellectual property (IP) laws, practices, and enforcement mechanisms are considered inadequate or unfair by the United States.

Three Designation Tiers

Section 301 Investigation: A formal inquiry that can lead to US trade sanctions, increased tariffs, or removal of trade preferences.

India’s IP Concerns — USTR’s Findings (2026)

1. Pharmaceutical Patent Linkage

• India’s drug regulator (CDSCO) approves generic drugs without checking whether originator patents are still active
• US wants a “patent linkage” system where regulatory approval is linked to patent status
• India opposes this as it would delay affordable generics — a public health concern

2. Section 3(d) of the Indian Patents Act

• India’s Section 3(d) (Patents Act, 1970, amended 2005) prevents “evergreening” — patenting of minor modifications of existing molecules
• USTR considers this an undue restriction on pharmaceutical patent protection
• India defends it as essential for access to affordable medicines

3. Copyright Enforcement

• USTR flags inadequate action against online piracy, cable signal theft, and digital copyright infringement
• Delays in criminal prosecution of IP infringement

4. Trade Secret Protection

• India lacks dedicated trade secret legislation (unlike the US Defend Trade Secrets Act, 2016)
• Trade secret protection is fragmented across contract law and common law

5. Enforcement Delays

• Lengthy court proceedings for IP infringement cases
• Inconsistent application of IP laws across states

India’s Position

India has consistently rejected the Special 301 methodology as:

1. Unilateral — the US acts as both judge and complainant
2. Incompatible with TRIPS — India’s IP regime is WTO-compliant under the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights)
3. Biased against access to medicines — Section 3(d) is a deliberate public health safeguard, upheld by Indian courts
4. Economically motivated — protects US pharmaceutical companies’ profits, not global IP norms

India has challenged US IP pressures at the WTO and in bilateral trade negotiations.

Vietnam as Priority Foreign Country

Vietnam’s PFC designation (2026) reflects:

• Inadequate copyright protection for digital content
• Weak pharmaceutical IP enforcement
• Large-scale piracy of US software, films, and music
• Last designated PFC in 2013; restored in 2026 due to persistent non-compliance
• Potential outcome: USTR could initiate a Section 301 investigation leading to tariffs on Vietnamese imports

India–US Trade Relations Context

UPSC Relevance

Mains Keywords: USTR Special 301 Report, Priority Watch List, Priority Foreign Country, Section 301, TRIPS Agreement, Section 3(d) Patents Act, pharmaceutical patent linkage, evergreening, India–US trade relations, IP enforcement, WTO compatibility

Prelims Facts Corner